Neparidze Natalia, Lacy Jill
Yale -University School of Medicine,West Haven, Connecticut.
Clin Adv Hematol Oncol. 2014 Jun;12(6):358-71.
Epstein-Barr virus (EBV) is associated with a wide variety of B-cell-derived lymphoid neoplasms, including Burkitt lymphoma, lymphomas arising in immunocompromised patients (post-transplant and HIV-associated lymphomas), and Hodgkin lymphoma. In addition, EBV has been linked to some T-cell lymphomas (angioimmunoblastic T-cell lymphoma, extranodal nasal-type natural killer/T-cell lymphoma, and other rare histotypes), nasopharyngeal cancer, and a subset of gastric cancers. Advances in our understanding of the pathobiology of EBV oncogenesis, including the transforming and immunogenic properties of the virus and the role of immune dysregulation, have provided the rationale for new treatment strategies. Emerging EBV-specific therapeutic approaches include activation of lytic viral infection combined with antiviral drugs, inhibition of EBV-induced oncogenic cellular signaling pathways, adoptive EBV-specific T-cell therapies, and EBV vaccines. This review summarizes the pathobiology, clinical features, and treatment of EBV-associated malignancies, including new and evolving therapies focused on exploiting the pathobiology of EBV.
爱泼斯坦-巴尔病毒（EBV）与多种B细胞来源的淋巴样肿瘤相关，包括伯基特淋巴瘤、免疫功能低下患者（移植后和HIV相关淋巴瘤）发生的淋巴瘤以及霍奇金淋巴瘤。此外，EBV还与一些T细胞淋巴瘤（血管免疫母细胞性T细胞淋巴瘤、结外鼻型自然杀伤/T细胞淋巴瘤及其他罕见组织学类型）、鼻咽癌以及一部分胃癌有关。我们对EBV致癌病理生物学的理解取得了进展，包括病毒的转化和免疫原性特性以及免疫失调的作用，这为新的治疗策略提供了理论依据。新兴的针对EBV的治疗方法包括激活裂解性病毒感染并联合使用抗病毒药物、抑制EBV诱导的致癌细胞信号通路、过继性EBV特异性T细胞疗法以及EBV疫苗。本综述总结了EBV相关恶性肿瘤的病理生物学、临床特征和治疗方法，包括专注于利用EBV病理生物学的新的和不断发展的疗法。
